Hypogonadism Treatment Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 3.00 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Hypogonadism Treatment Market Analysis
The Hypogonadism Treatment Market is expected to register a CAGR of 3% during the forecast period attributing to increase in the incidence of hypogonadism, a rise in awareness about the disease and its treatment options and growth of infertility rate. Moreover, high risk of hypogonadism in the geriatric population and patient pool with diabetes and obesity are also some of the key drivers in the hypogonadism treatment market. For instance, according to a report published by the National Institute of Health (NIH), in 2019 obesity is increasing worldwide and the prevalence of hypogonadism is significantly greater in males with obesity. In addition, men aged between 60-80 years have low testosterone levels by 20% and 80% than normal testosterone levels in young men. Men above 60 years have the highest prevalence of hypogonadism. Thus, countries surging the geriatric population are witnessing a high demand for therapies to treat hypogonadism, hence, driving the hypogonadism market.
Hypogonadism Treatment Market Trends
This section covers the major market trends shaping the Hypogonadism Treatment Market according to our research experts:
In Treatment Type Segment, Testosterone Replacement Therapy is Expected to Witness a Healthy Growth in Future
Testosterone replacement therapy is expected to contribute the largest revenue considering the fact that hypogonadism is more prevalent in men. Several government initiatives and product approvals are also boosting the testosterone replacement therapy. For instance, Clarus Therapeutics, in May 2019, received the FDA approval for Jatenzo testosterone, an oral testosterone replacement therapy for the treatment of primary hypogonadism and hypogonadotropic hypogonadism in men. In addition, Antares Pharma received the FDA approval in 2018 for Xyosted (testosterone enanthate) Injection.
In addition, the decreasing rate of fertility is leading to the high chances of hypogonadism and promoting the revenue growth of the overall market
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to dominate the global hypogonadism treatment market throughout the forecast period. This dominance is mainly owing to increasing cases of hypogonadism with raising awareness about the hormonal disorder, increased adoption of newer highly advanced products and advanced healthcare infrastructure. As per the report published in the European Association of Urology Journal in the year 2017, testosterone prescription trends in the United States witnessed an increase between 1.8 and 4-fold over the last two decades (1997 - 2017) which is resulting in the growth of hypogonadism market.
Hypogonadism Treatment Industry Overview
The market studied is moderately competitive and there are several international companies present in this market. Some of the companies in the market are Abbott Laboratories Inc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Endo International, Ferring Pharmaceuticals, AbbVie Inc. and Merck Serono.
Hypogonadism Treatment Market Leaders
-
Abbott Laboratories Inc
-
Eli Lilly and Company
-
Teva Pharmaceutical Industries Ltd
-
Endo International
-
Ferring Pharmaceuticals
*Disclaimer: Major Players sorted in no particular order
Hypogonadism Treatment Market Report - Table of Contents
-
1. INTRODUCTION
-
1.1 Study Assumptions
-
1.2 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 High Risk of Hypogonadism in Geriatric Population
-
4.2.2 Lifestyle Issues
-
-
4.3 Market Restraints
-
4.3.1 Social Taboo
-
-
4.4 Porter's Five Force Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Type
-
5.1.1 Primary Hypogonadism
-
5.1.2 Central Hypogonadism
-
-
5.2 By Treatment Type
-
5.2.1 Testosterone Replacement Therapy
-
5.2.2 Estrogen Therapy
-
5.2.3 Progesterone Therapy
-
-
5.3 By Route of Administration
-
5.3.1 Topical Gel
-
5.3.2 Transdermal Patch
-
5.3.3 Implantable Pellet
-
5.3.4 Oral Tablets
-
5.3.5 Others
-
-
5.4 By End User
-
5.4.1 Hospitals
-
5.4.2 Speciality Clinics
-
5.4.3 Others
-
-
5.5 Geography
-
5.5.1 North America
-
5.5.1.1 United States
-
5.5.1.2 Canada
-
5.5.1.3 Mexico
-
-
5.5.2 Europe
-
5.5.2.1 Germany
-
5.5.2.2 United Kingdom
-
5.5.2.3 France
-
5.5.2.4 Italy
-
5.5.2.5 Spain
-
5.5.2.6 Rest of Europe
-
-
5.5.3 Asia-Pacific
-
5.5.3.1 China
-
5.5.3.2 Japan
-
5.5.3.3 India
-
5.5.3.4 Australia
-
5.5.3.5 South Korea
-
5.5.3.6 Rest of Asia-Pacific
-
-
5.5.4 Middle-East and Africa
-
5.5.4.1 GCC
-
5.5.4.2 South Africa
-
5.5.4.3 Rest of Middle-East and Africa
-
-
5.5.5 South America
-
5.5.5.1 Brazil
-
5.5.5.2 Argentina
-
5.5.5.3 Rest of South America
-
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 Abbott Laboratories Inc
-
6.1.2 Eli Lilly and Company
-
6.1.3 Teva Pharmaceutical Industries Ltd
-
6.1.4 Endo International
-
6.1.5 Ferring Pharmaceuticals
-
6.1.6 AbbVie Inc.
-
6.1.7 Merck Serono
-
- *List Not Exhaustive
-
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Hypogonadism Treatment Industry Segmentation
Hypogonadism is a rare hormonal disorder characterized by insufficient production of testes or ovaries, result in diminished production of sex hormones. Hypogonadism Treatment Market is segmented By Type, Treatment Type, Route of Administration and Geography.
| By Type | |
| Primary Hypogonadism | |
| Central Hypogonadism |
| By Treatment Type | |
| Testosterone Replacement Therapy | |
| Estrogen Therapy | |
| Progesterone Therapy |
| By Route of Administration | |
| Topical Gel | |
| Transdermal Patch | |
| Implantable Pellet | |
| Oral Tablets | |
| Others |
| By End User | |
| Hospitals | |
| Speciality Clinics | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Hypogonadism Treatment Market Research FAQs
What is the current Hypogonadism Treatment Market size?
The Hypogonadism Treatment Market is projected to register a CAGR of 3% during the forecast period (2024-2029)
Who are the key players in Hypogonadism Treatment Market?
Abbott Laboratories Inc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Endo International and Ferring Pharmaceuticals are the major companies operating in the Hypogonadism Treatment Market.
Which is the fastest growing region in Hypogonadism Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Hypogonadism Treatment Market?
In 2024, the North America accounts for the largest market share in Hypogonadism Treatment Market.
What years does this Hypogonadism Treatment Market cover?
The report covers the Hypogonadism Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Hypogonadism Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Hypogonadism Treatment Industry Report
Statistics for the 2024 Hypogonadism Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Hypogonadism Treatment analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
Hypogonadism Treatment Report Snapshots
